Interview with Alberto Grua, Managing Director, Grunenthal Italy
Grunenthal-Formenti relies on Formenti’s 60 years experience in Italy and is the result of the merger of both the German and Italian entities in 96. How would you describe the…
Address: Via Koch 1/2, 20152 Milano,Italy
Tel: -43014
Web: http://www.grunenthal.it/grt-web/Grunenthal_Formenti_-_Italia/80600016.jsp
Grunenthal is an Italian independent pharmaceutical company based on research with national and international operations. It has always been a company with private capital since its founding in 1946. Grunenthal products are marketed in over 80 countries and the number of branches is growing. Grunenthal employs approximately 4,800 people worldwide.Grunenthal’s ambition is to be a leader in research and development in fields related to pain aliviation.
Grunenthal-Formenti relies on Formenti’s 60 years experience in Italy and is the result of the merger of both the German and Italian entities in 96. How would you describe the…
Dompé’s Chief Operating Officer, Eriona Gjinukaj, responsible for creating the Italian mid-cap’s US affiliate, reveals the challenges and rewards of that experience and explains how she saw the company go…
UCB Italy’s Managing Director, Federico Chinni offeres his insights into UCB’s positioning and its new product launches, the first for the company in ten years. He also weighs in on…
GeneraLife, an in vitro fertilisation (IVF) clinic group with 14 clinics in Italy as well as in a number of other countries. The group’s Director of the Scientific Executive Committee,…
ENEA Tech and Biomedical is a foundation supervised by the Italian Ministry of Economic Development that aims to strengthen Italian R&D and the industrial transformation of the country’s biomedical sector.…
Italy, Europe’s fourth largest pharma market at a size of EUR 23.446 billion, has a highly decentralised healthcare system, with the country’s 20 regions negotiating market access for medicines individually…
Pierre Fabre Italy’s Charles-Henri Bodin highlights how the French firm’s offering has expanded far beyond its dermo-cosmetics heritage to today encompass a wide range of pharmaceuticals, including the key growth…
Domenico Mantoan, General Manager of AGENAS, the Italian National Agency for Regional Health Services, discusses the role of the agency in Italy’s decentralised healthcare system, the National Recovery and Resilience…
Nicoletta Luppi, MSD Italia’s Senior Vice President & Managing Director details the need for healthcare reform in Italy and walks us through MSD’s portfolio priorities. In addition, she explains the…
In recent years, since the adoption of a law assuring its citizens’ right to access palliative care, Italy has given increased attention to pain management. According to Aldo Sterpone, Italy…
Aldo Sterpone, Grünenthal Italia’s General Manager, outlines the company’s focus on pain and its efforts to bring innovation to the area through R&D and acquisitions. He also explains the importance…
We spoke with Luca Crippa, CEO and Managing Director at IBSA Farmaceutici, about the company’s approach to developing new delivery technologies for existing and natural molecules, its focus on endocrinology,…
Stevanato Group’s CEO & COO, Franco Moro explaines how the over 70-year-old provider of containment and delivery solutions went public and as an established player in the vaccine space managed…
See our Cookie Privacy Policy Here
